Bauer, Martin

[["dc.bibliographiccitation.artnumber","e2035"],["dc.bibliographiccitation.issue","45"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ameen, Abu Hanna"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Brandes, Ivo Florian"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:49:09Z"],["dc.date.available","2018-11-07T09:49:09Z"],["dc.date.issued","2015"],["dc.description.abstract","Hyperglycemia is common during and after Coronary Artery Bypass Graft Surgery (CABGS) and has been shown to be associated with poor clinical outcomes. In this study, we hypothesized that a moderate perioperative mean blood glucose level of<150mg/dL improves long-term survival in cardiac surgery patients. We conducted a prospective, observational cohort study in the heart center of the University Medical Center of Goettingen, Germany. Patients undergoing on-pump cardiac surgery were enrolled in this investigation. After evaluating perioperative blood glucose levels, patients were classified into 2 groups based on mean glucose levels: Glucose 150mg/dL and Glucose<150mg/dL. Patients were followed up for 5 years, and mortality within this period was recorded as the primary outcome parameter. Secondary outcome parameters included the length of ICU stay, the use of inotropic agents, the length of hospital stay, and the in-hospital mortality. A total of 455 consecutive patients who underwent cardiac surgery with cardiopulmonary bypass were enrolled in this investigation. A Kaplan-Meier survival analysis of the 5-year mortality risk revealed a higher mortality risk among patients with glucose levels 150mg/dL (P=0.0043, log-rank test). After adjustment for confounders in a multivariate Cox regression model, the association between glucose 150mg/dL and 5-year mortality remained significant (hazard ratio, 2.10; 95% CI, 1.30-3.39; P=0.0023). This association was corroborated by propensity score matching, in which Kaplan-Meier survival analysis demonstrated significant improvement in the 5-year survival of patients with glucose levels<150mg/dL (P=0.0339). Similarly, in-hospital mortality was significantly higher in patients with glucose 150mg/dL compared with patients with glucose<150mg/dL. Moreover, patients in the Glucose 150mg/dL group required significantly higher doses of the inotropic agent Dobutamine (mg/d) compared with patients in the Glucose<150mg/dL group (20.6 +/- 62.3 and 10.5 +/- 40.7, respectively; P=0.0104). Moreover, patients in the Glucose 150mg/dL group showed a significantly longer hospital stay compared with patients in the Glucose<150mg/dL group (28 +/- 23 and 24 +/- 19, respectively; P=0.0297). We conclude that perioperative blood glucose levels<150mg/dL are associated with improved 5-year survival in patients undergoing cardiac surgery. More studies are warranted to explain this effect."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1097/MD.0000000000002035"],["dc.identifier.isi","000369537400066"],["dc.identifier.pmid","26559310"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12570"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35449"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nd/4.0"],["dc.title","Perioperative Blood Glucose Levels < 150 mg/dL are Associated With Improved 5-Year Survival in Patients Undergoing On-Pump Cardiac Surgery A Prospective, Observational Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","128"],["dc.bibliographiccitation.journal","BMC Medicine"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:56:35Z"],["dc.date.available","2018-11-07T09:56:35Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Previous investigations have presumed a potential therapeutic effect of statin therapy in patients with acute respiratory distress syndrome (ARDS). Statins are expected to attenuate inflammation in the lungs of patients with ARDS due to their anti-inflammatory effects. Clinical investigations of the role of statin therapy have revealed contradictory results. This study aimed to investigate whether pretreatment and continuous therapy with statins in patients with sepsis-associated ARDS are associated with 28-day survival according to disease severity (mild, moderate, or severe). Methods: Patients with sepsis-associated ARDS from the surgical intensive care were enrolled in this prospective observational investigation. ARDS was classified into three groups (mild, moderate, and severe); 28-day mortality was recorded as the primary outcome variable and organ failure was recorded as secondary outcome variable. Sequential Organ Failure Assessment scores and the requirements for organ support were evaluated throughout the observational period to assess organ failure. Results: 404 patients with sepsis-associated ARDS were enrolled in this investigation. The distribution of the ARDS subgroups was 13 %, 59 %, and 28 % for mild, moderate, and severe disease, respectively. Statin therapy improved 28-day survival exclusively in the patients with severe ARDS compared with patients without statin therapy (88.5 % and 62.5 %, respectively; P = 0.0193). To exclude the effects of several confounders, we performed multivariate Cox regression analysis, which showed that statin therapy remained a significant covariate for mortality (hazard ratio, 5.46; 95 % CI, 1.38-21.70; P = 0.0156). Moreover, after carrying a propensity score-matching in the severe ARDS cohort, Kaplan-Meier survival analysis confirmed the improved 28-day survival among patients with statin therapy (P = 0.0205). Patients with severe ARDS who received statin therapy had significantly more vasopressor-free days compared with those without statin therapy (13 +/- 7 and 9 +/- 7, respectively; P = 0.0034), and they also required less extracorporeal membrane oxygenation (ECMO) therapy and had more ECMO-free days (18 +/- 9 and 15 +/- 9, respectively; P = 0.0873). Conclusions: This investigation suggests a beneficial effect of continuous statin therapy in patients with severe sepsis-associated ARDS and a history of prior statin therapy. Further study is warranted to elucidate this potential effect."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s12916-015-0368-6"],["dc.identifier.isi","000355790700001"],["dc.identifier.pmid","26033076"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36986"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1741-7015"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0127761"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Liese, Benjamin"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:57:00Z"],["dc.date.available","2018-11-07T09:57:00Z"],["dc.date.issued","2015"],["dc.description.abstract","According to previous investigations, CD14 is suggested to play a pivotal role in initiating and perpetuating the pro-inflammatory response during sepsis. A functional polymorphism within the CD14 gene, rs2569190, has been shown to impact the pro-inflammatory response upon stimulation with lipopolysaccharide, a central mediator of inflammation in sepsis. In this study, we hypothesized that the strong pro-inflammatory response induced by the TT genotype of CD14 rs2569190 may have a beneficial effect on survival (30-day) in patients with sepsis. A total of 417 adult patients with sepsis (and of western European descent) were enrolled into this observational study. Blood samples were collected for rs2569190 genotyping. Patients were followed over the course of their stay in the ICU, and the 30-day mortality risk was recorded as the primary outcome parameter. Sepsis-related organ failure assessment (SOFA) scores were quantified at sepsis onset and throughout the observational period to monitor organ failure as a secondary variable. Moreover, organ support-free days were evaluated as a secondary outcome parameter. TT-homozygous patients were compared to C-allele carriers. Kaplan-Meier survival analysis revealed a higher 30-day mortality risk among C-allele carriers compared with T homozygotes (p = 0.0261). To exclude the effect of potential confounders (age, gender, BMI and type of infection) and covariates that varied at baseline with a p-value < 0.2 (e.g., comorbidities), we performed multivariate Cox regression analysis to examine the survival time. The CD14 rs2569190 C allele remained a significant covariate for the 30-day mortality risk in the multivariate analysis (hazard ratio, 2.11; 95% CI, 1.08-4.12; p = 0.0282). The 30-day mortality rate among C allele carriers was 23%, whereas the T homozygotes had a mortality rate of 13%. Additionally, an analysis of organ-specific SOFA scores revealed a significantly higher SOFA-Central nervous system score among patients carrying the C allele compared with T-homozygous patients (1.9 +/- 1.1 and 1.6 +/- 1.0, respectively; p = 0.0311). In conclusion, CD14 rs2569190 may act as a prognostic variable for the short-term outcome (30-day survival) in patients with sepsis."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1371/journal.pone.0127761"],["dc.identifier.isi","000355187300054"],["dc.identifier.pmid","26020644"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11869"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37077"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The CD14 rs2569190 TT Genotype Is Associated with an Improved 30-Day Survival in Patients with Sepsis: A Prospective Observational Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e006616"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Klee, Yvonne"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Erlenwein, Joachim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T10:03:51Z"],["dc.date.available","2018-11-07T10:03:51Z"],["dc.date.issued","2015"],["dc.description.abstract","Objective: To investigate whether common infection foci (pulmonary, intra-abdominal and primary bacteraemia) are associated with variations in mortality risk in patients with sepsis. Design: Prospective, observational cohort study. Setting: Three surgical intensive care units (ICUs) at a university medical centre. Participants: A total of 327 adult Caucasian patients with sepsis originating from pulmonary, intra-abdominal and primary bacteraemia participated in this study. Primary and secondary outcome measures: The patients were followed for 90 days and mortality risk was recorded as the primary outcome variable. To monitor organ failure, sepsis-related organ failure assessment (Sequential Organ Failure Assessment, SOFA) scores were evaluated at the onset of sepsis and throughout the observational period as secondary outcome variables. Results: A total of 327 critically ill patients with sepsis were enrolled in this study. Kaplan-Meier survival analysis showed that the 90-day mortality risk was significantly higher among patients with primary bacteraemia than among those with pulmonary and intra-abdominal foci (58%, 35% and 32%, respectively; p=0.0208). To exclude the effects of several baseline variables, we performed multivariate Cox regression analysis. Primary bacteraemia remained a significant covariate for mortality in the multivariate analysis (HR 2.10; 95% CI 1.14 to 3.86; p=0.0166). During their stay in the ICU, the patients with primary bacteraemia presented significantly higher SOFA scores than those of the patients with pulmonary and intra-abdominal infection foci (8.5 +/- 4.7, 7.3 +/- 3.4 and 5.8 +/- 3.5, respectively). Patients with primary bacteraemia presented higher SOFA-renal score compared with the patients with other infection foci (1.6 +/- 1.4, 0.8 +/- 1.1 and 0.7 +/- 1.0, respectively); the patients with primary bacteraemia required significantly more renal replacement therapy than the patients in the other groups (29%, 11% and 12%, respectively). Conclusions: These results indicate that patients with sepsis with primary bacteraemia present a higher mortality risk compared with patients with sepsis of pulmonary or intra-abdominal origins. These results should be assessed in patients with sepsis in larger, independent cohorts."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1136/bmjopen-2014-006616"],["dc.identifier.isi","000348171800032"],["dc.identifier.pmid","25564146"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11567"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38567"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","2044-6055"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Primary bacteraemia is associated with a higher mortality risk compared with pulmonary and intra-abdominal infections in patients with sepsis: a prospective observational cohort study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","10539"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Mulwande, Evelyn"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:57:04Z"],["dc.date.available","2018-11-07T09:57:04Z"],["dc.date.issued","2015"],["dc.description.abstract","According to previous studies, the clinical course of sepsis could be affected by preexisting medical conditions, which are very common among patients with sepsis. This observational study aimed at investigating whether common chronic medical conditions affect the 90-day mortality risk in adult Caucasian patients with sepsis. A total of 482 patients with sepsis were enrolled in this study. The ninety-day mortality was the primary outcome; organ failure was the secondary outcome. Sepsis-related organ failure assessment (SOFA) scores and the requirements for organ support were evaluated to assess organ failure. A multivariate Cox regression model for the association between the 90-day mortality risk and chronic preexisting medical conditions adjusted for all relevant confounders and mortality predictors revealed the highest hazard ratio for patients with chronic kidney disease (CKD) (hazard ratio, 2.25; 95% CI, 1.46-3.46; p = 0.0002). Patients with CKD had higher SOFA scores than patients without CKD (8.9 perpendicular to 4.0 and 6.5 perpendicular to 3.4, respectively; p < 0.0001). Additionally, an analysis of organ-specific SOFA scores revealed higher scores in three organ systems (kidney, cardiovascular and coagulation). Patients with CKD have the highest 90-day mortality risk compared with patients without CKD or with other chronic medical conditions."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1038/srep10539"],["dc.identifier.isi","000355509300001"],["dc.identifier.pmid","25995131"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37088"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","R153"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","CRITICAL CARE"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Toischer, Karl"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Renner, Andre"],["dc.contributor.author","Schmitto, Jan Dieter"],["dc.contributor.author","Gummert, J. F."],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Maier, Lars S."],["dc.contributor.author","Sossalla, Samuel Tobias"],["dc.date.accessioned","2018-11-07T09:14:39Z"],["dc.date.available","2018-11-07T09:14:39Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction: Pronounced extracellular acidosis reduces both cardiac contractility and the beta-adrenergic response. In the past, this was shown in some studies using animal models. However, few data exist regarding how the human end-stage failing myocardium, in which compensatory mechanisms are exhausted, reacts to acute mild metabolic acidosis. The aim of this study was to investigate the effect of mild metabolic acidosis on contractility and the beta-adrenergic response of isolated trabeculae from human end-stage failing hearts. Methods: Intact isometrically twitching trabeculae isolated from patients with end-stage heart failure were exposed to mild metabolic acidosis (pH 7.20). Trabeculae were stimulated at increasing frequencies and finally exposed to increasing concentrations of isoproterenol (0 to 1 x 10(-6) M). Results: A mild metabolic acidosis caused a depression in twitch-force amplitude of 26% (12.1 +/- 1.9 to 9.0 +/- 1.5 mN/mm(2); n = 12; P < 0.01) as compared with pH 7.40. Force-frequency relation measurements yielded no further significant differences of twitch force. At the maximal isoproterenol concentration, the force amplitude was comparable in each of the two groups (pH 7.40 versus pH 7.20). However, the half-maximal effective concentration (EC50) was significantly increased in the acidosis group, with an EC50 of 5.834 x 10(-8) M (confidence interval (CI), 3.48 x 10(-8) to 9.779 x 10(-8); n = 9), compared with the control group, which had an EC50 of 1.056 x 10(-8) M (CI, 2.626 x 10(-9) to 4.243 x 10(-8); n = 10; P < 0.05), indicating an impaired beta-adrenergic force response. Conclusions: Our data show that mild metabolic acidosis reduces cardiac contractility and significantly impairs the beta-adrenergic force response in human failing myocardium. Thus, our results could contribute to the still-controversial discussion about the therapy regimen of acidosis in patients with critical heart failure."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/cc11468"],["dc.identifier.isi","000313197800040"],["dc.identifier.pmid","22889236"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27466"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1466-609X"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Mild metabolic acidosis impairs the beta-adrenergic response in isolated human failing myocardium"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e1619"],["dc.bibliographiccitation.journal","PeerJ"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Hinz, Jose"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Hanekop, Gerd-Gunnar"],["dc.contributor.author","Weyland, Andreas"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Schmitto, Jan Dieter"],["dc.contributor.author","Grune, Frank F. G."],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Kazmaier, Stephan"],["dc.date.accessioned","2018-11-07T10:19:11Z"],["dc.date.available","2018-11-07T10:19:11Z"],["dc.date.issued","2016"],["dc.description.abstract","The effects of isoflurane on the determinants of blood flow during Coronary Artery Bypass Graft (CABG) surgery are not completely understood. This study characterized the influence of isoflurane on the diastolic Pressure-Flow (P-F) relationship and Critical Occlusion Pressure (COP) during CABG surgery. Twenty patients undergoing CABG surgery were studied. Patients were assigned to an isoflurane or control group. Hemodynamic and flow measurements during CABG surgery were performed twice (15 minutes after the discontinuation of extracorporeal circulation (T15) and again 15 minutes later (T30)). The zero flow pressure intercept (a measure of COP) was extrapolated from a linear regression analysis of the instantaneous diastolic P-F relationship. In the isoflurane group, the application of isoflurane significantly increased the slope of the diastolic P-F relationship by 215% indicating a mean reduction of Coronary Vascular Resistance (CVR) by 46%. Simultaneously, the Mean Diastolic Aortic Pressure (MDAP) decreased by 19% mainly due to a decrease in the systemic vascular resistance index by 21%. The COP, cardiac index, heart rate, Left Ventricular End-Diastolic Pressure (LVEDP) and Coronary Sinus Pressure (CSP) did not change significantly. In the control group, the parameters remained unchanged. In both groups, COP significantly exceeded the CSP and LVEDP at both time points. We conclude that short-term application of isoflurane at a sedative concentration markedly increases the slope of the instantaneous diastolic P-F relationship during CABG surgery implying a distinct decrease with CVR in patients undergoing CABG surgery."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2016"],["dc.identifier.doi","10.7717/peerj.1619"],["dc.identifier.isi","000369406400004"],["dc.identifier.pmid","26966644"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12920"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41614"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Peerj Inc"],["dc.relation.issn","2167-8359"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Influence of isoflurane on the diastolic pressure-flow relationship and critical occlusion pressure during arterial CABG surgery: a randomized controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","177"],["dc.bibliographiccitation.journal","Journal of Translational Medicine"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","von Gruben, Luisa"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Ross, Daniel"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:38:51Z"],["dc.date.available","2018-11-07T09:38:51Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Toll-like receptor 4 (TLR4), a lipopolysaccharide (LPS) receptor complex signal-transducing molecule, plays a crucial role in sensing LPS from gram-negative bacteria. TLR4 signaling pathway activation by LPS plays a major role in sepsis pathogenesis. A single nucleotide polymorphism, rs11536889, in the 3'-untranslated region of the TLR4 gene is thought to affect TLR4 translation. This study aimed to investigate whether organ failure in sepsis patients is related to the TLR4 rs11536889 genotype. Methods: Adult Caucasian patients with sepsis from the intensive care unit of a university medical center were followed up for 90 days, and organ failure was recorded as the primary outcome variable. Blood samples were collected at enrollment for TLR4 rs11536889 genotyping. Sepsis-related organ failure assessment (SOFA) scores were quantified at sepsis onset and throughout the observational period to monitor organ failure. Results: A total of 210 critically ill patients with sepsis were enrolled into this study. Wild-type GG was compared to GC/CC. During their stay in the intensive care unit, GG patients presented significantly higher SOFA scores than did C allele carriers (7.9 +/- 4.5 and 6.8 +/- 4.2, respectively; p = 0.0005). Analysis of organ-specific SOFA sub-scores revealed significant differences in three organ systems: renal, coagulation and hepatic (p = 0.0005, p = 0.0245 and p < 0.0001, respectively). Additionally, the rs11536889 polymorphism was associated with a higher incidence of gram-negative infections. Conclusions: These results offer the first evidence that TLR4 rs11536889 is a useful marker of organ failure in patients with sepsis."],["dc.identifier.doi","10.1186/1479-5876-12-177"],["dc.identifier.isi","000339026200001"],["dc.identifier.pmid","24950711"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10433"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33149"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1479-5876"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is associated with renal, coagulation and hepatic organ failure in sepsis patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]